{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:31:30Z","timestamp":1794562290622,"version":"4.9.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100017957","name":"Health Commission of Guizhou Province","doi-asserted-by":"publisher","award":["2021XMSB00032675"],"award-info":[{"award-number":["2021XMSB00032675"]}],"id":[{"id":"10.13039\/100017957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260584"],"award-info":[{"award-number":["82260584"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004001","name":"Guizhou Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["[2022]-193"],"award-info":[{"award-number":["[2022]-193"]}],"id":[{"id":"10.13039\/501100004001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004001","name":"Guizhou Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["[2023]-373"],"award-info":[{"award-number":["[2023]-373"]}],"id":[{"id":"10.13039\/501100004001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004001","name":"Guizhou Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["ZK [ 2023 ]-359"],"award-info":[{"award-number":["ZK [ 2023 ]-359"]}],"id":[{"id":"10.13039\/501100004001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jpet.2026.105012","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:56:02Z","timestamp":1787064962000},"page":"105012","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Shiheleucel, an allogeneic natural killer cell product expanded under chemically defined conditions, in combination with rituximab-based chemotherapy in relapsed\/refractory diffuse large B-cell lymphoma: An exploratory clinical study"],"prefix":"10.1016","volume":"393","author":[{"given":"Yunhong","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingling","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jindan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunqiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongjie","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7918-9269","authenticated-orcid":false,"given":"Yuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jpet.2026.105012_bib1","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jpet.2026.105012_bib2","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ajh.26151","article-title":"2021 update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management","volume":"96","author":"Susanibar-Adaniya","year":"2021","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.jpet.2026.105012_bib3","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.3324\/haematol.2023.284704","article-title":"Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy","volume":"109","author":"Tun","year":"2024","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.jpet.2026.105012_bib4","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/asheducation-2016.1.366","article-title":"Diffuse large B-cell lymphoma: R-CHOP failure-what to do?","volume":"2016","author":"Coiffier","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"21","key":"10.1016\/j.jpet.2026.105012_bib5","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1056\/NEJMct1114348","article-title":"Anti-CD20 antibody therapy for B-cell lymphomas","volume":"366","author":"Maloney","year":"2012","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jpet.2026.105012_bib6","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience","volume":"34","author":"Salles","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.jpet.2026.105012_bib7","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3389\/fimmu.2017.01245","article-title":"Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going?","volume":"8","author":"Marshall","year":"2017","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.jpet.2026.105012_bib8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.21037\/atm.2019.01.42","article-title":"NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives","volume":"7","author":"Lo Nigro","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jpet.2026.105012_bib9","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3389\/fimmu.2015.00368","article-title":"NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy","volume":"6","author":"Wang","year":"2015","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.jpet.2026.105012_bib10","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.3390\/jcm8101557","article-title":"NK cells in the treatment of hematological malignancies","volume":"8","author":"Gonzalez-Rodriguez","year":"2019","journal-title":"J Clin Med"},{"issue":"7","key":"10.1016\/j.jpet.2026.105012_bib11","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1093\/annonc\/mdm110","article-title":"Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2\u20133 diffuse large B-cell lymphoma","volume":"18","author":"Plonquet","year":"2007","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.jpet.2026.105012_bib12","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00262-017-2100-1","article-title":"Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells","volume":"67","author":"Bachanova","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jpet.2026.105012_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2022.104615","article-title":"Dampening of cytotoxic innate lymphoid cells: a new tumour immune escape mechanism in B cell non-Hodgkin\u2019s lymphoma","volume":"382","author":"Roma","year":"2022","journal-title":"Cell Immunol"},{"issue":"5","key":"10.1016\/j.jpet.2026.105012_bib14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nri2073","article-title":"Prospects for the use of NK cells in immunotherapy of human cancer","volume":"7","author":"Ljunggren","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jpet.2026.105012_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2019.03.004","article-title":"NK cells to cure cancer","volume":"41","author":"Di Vito","year":"2019","journal-title":"Semin Immunol"},{"issue":"11","key":"10.1016\/j.jpet.2026.105012_bib16","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.3390\/cancers12113139","article-title":"Natural killer cells in immunotherapy: are we nearly there?","volume":"12","author":"Bachiller","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.jpet.2026.105012_bib17","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41423-021-00808-3","article-title":"Advances in NK cell production","volume":"19","author":"Fang","year":"2022","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"10.1016\/j.jpet.2026.105012_bib18","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13045-022-01382-5","article-title":"Natural killer cells in clinical development as non-engineered, engineered, and combination therapies","volume":"15","author":"Lamers-Kok","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.jpet.2026.105012_bib19","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2004-12-4797","article-title":"Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells","volume":"106","author":"Imai","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jpet.2026.105012_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030264","article-title":"Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells","volume":"7","author":"Denman","year":"2012","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.jpet.2026.105012_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076781","article-title":"Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity","volume":"8","author":"Shah","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jpet.2026.105012_bib22","doi-asserted-by":"crossref","first-page":"274","DOI":"10.5966\/sctm.2012-0084","article-title":"Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy","volume":"2","author":"Knorr","year":"2013","journal-title":"Stem Cells Transl Med"},{"issue":"3","key":"10.1016\/j.jpet.2026.105012_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212455","article-title":"Ex vivo-expanded highly purified natural killer cells in combination with temozolomide induce antitumor effects in human glioblastoma cells in vitro","volume":"14","author":"Tanaka","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jpet.2026.105012_bib24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.reth.2023.05.006","article-title":"An efficient feeder-free and chemically-defined expansion strategy for highly purified natural killer cells derived from human cord blood","volume":"24","author":"Nakazawa","year":"2023","journal-title":"Regen Ther"},{"issue":"1","key":"10.1016\/j.jpet.2026.105012_bib25","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13045-020-00871-9","article-title":"A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma","volume":"13","author":"Shi","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"8000","key":"10.1016\/j.jpet.2026.105012_bib26","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41586-023-06945-1","article-title":"Natural killer cell therapies","volume":"626","author":"Vivier","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.jpet.2026.105012_bib27","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3389\/fimmu.2017.00631","article-title":"The rise of allogeneic natural killer cells as a platform for cancer immunotherapy: recent innovations and future developments","volume":"8","author":"Veluchamy","year":"2017","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.jpet.2026.105012_bib28","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","article-title":"NK cells for cancer immunotherapy","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"10.1016\/j.jpet.2026.105012_bib29","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood.2022016200","article-title":"Allogeneic natural killer cell therapy","volume":"141","author":"Berrien-Elliott","year":"2023","journal-title":"Blood"},{"issue":"705","key":"10.1016\/j.jpet.2026.105012_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ade3341","article-title":"Nicotinamide enhances natural killer cell function and yields remissions in patients with non-Hodgkin lymphoma","volume":"15","author":"Cichocki","year":"2023","journal-title":"Sci Transl Med"},{"issue":"11","key":"10.1016\/j.jpet.2026.105012_bib31","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.jcyt.2016.06.013","article-title":"Expanded and armed natural killer cells for cancer treatment","volume":"18","author":"Shimasaki","year":"2016","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.jpet.2026.105012_bib32","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13045-025-01702-5","article-title":"Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: recent advances and emerging therapies","volume":"18","author":"Bock","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"19","key":"10.1016\/j.jpet.2026.105012_bib33","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jpet.2026.105012_bib34","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1200\/JCO-25-00507","article-title":"Five-year analysis of the JULIET trial of tisagenlecleucel in patients with relapsed\/refractory large B-cell lymphoma","volume":"44","author":"Maziarz","year":"2026","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jpet.2026.105012_bib35","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.23.02470","article-title":"Glofitamab in relapsed\/refractory mantle cell lymphoma: results from a phase I\/II study","volume":"43","author":"Phillips","year":"2025","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jpet.2026.105012_bib36","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","article-title":"Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial","volume":"38","author":"Thieblemont","year":"2024","journal-title":"Leukemia"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526012127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526012127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:17:22Z","timestamp":1794561442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356526012127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0022356526012127"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2026.105012","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Shiheleucel, an allogeneic natural killer cell product expanded under chemically defined conditions, in combination with rituximab-based chemotherapy in relapsed\/refractory diffuse large B-cell lymphoma: An exploratory clinical study","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2026.105012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105012"}}